Nature.2021.06.12 [Sat, 12 Jun 2021]

Total Page:16

File Type:pdf, Size:1020Kb

Nature.2021.06.12 [Sat, 12 Jun 2021] [Sat, 12 Jun 2021] This Week News in Focus Books & Arts Opinion Work Research | Next section | Main menu | Donation | Next section | Main menu | | Next section | Main menu | Previous section | This Week Embrace the WHO’s new naming system for coronavirus variants [09 June 2021] Editorial • The World Health Organization’s system should have come earlier. Now, media and policymakers need to get behind it. Google’s AI approach to microchips is welcome — but needs care [09 June 2021] Editorial • Artificial intelligence can help the electronics industry to speed up chip design. But the gains must be shared equitably. The replication crisis won’t be solved with broad brushstrokes [08 June 2021] World View • A cookie-cutter strategy to reform science will cause resentment, not improvement. A light touch changes the strength of a single atomic bond [07 June 2021] Research Highlight • A technique that uses an electric field to tighten the bond between two atoms can allow a game of atomic pick-up-sticks. How fit can you get? These blood proteins hold a clue [04 June 2021] Research Highlight • Scientists pinpoint almost 150 biomarkers linked to intrinsic cardiovascular fitness, and 100 linked to fitness gained from training. Complex, lab-made ‘cells’ react to change like the real thing [02 June 2021] Research Highlight • Synthetic structures that grow artificial ‘organelles’ could provide insights into the operation of living cells. Elephants’ trunks are mighty suction machines [01 June 2021] Research Highlight • The pachyderms can nab a treat lying nearly 5 centimetres away through sheer sucking power. More than one-third of heat deaths blamed on climate change [04 June 2021] Research Highlight • Warming resulting from human activities accounts for a high percentage of heat-related deaths, especially in southern Asia and South America. Pyramid made of dirt is world’s oldest known war memorial [27 May 2021] Research Highlight • Grave goods suggest that some of the people whose bones are buried in the Syrian monument were charioteers. The surprise hidden in the teeth of the ‘wandering meatloaf’ [02 June 2021] Research Highlight • The teeth of a marine mollusc hold the mineral santabarbaraite, which has been found in no other living thing. | Next section | Main menu | Previous section | | Next | Section menu | Main menu | EDITORIAL 09 June 2021 Embrace the WHO’s new naming system for coronavirus variants The World Health Organization’s system should have come earlier. Now, media and policymakers need to get behind it. Download PDF Coronavirus variants will now be named using Greek letters.Credit: Shutterstock It has taken nearly six months, but the World Health Organization (WHO) last week announced the first iteration of its naming system for two kinds of coronavirus variant, to be used in public communications. An expert committee advising the WHO recommended using the Greek alphabet to describe ‘variants of interest’ — which are coronavirus strains that lead to increased infections locally — as well as the more dangerous ‘variants of concern’. The long-awaited system is intended for use by the media, policymakers and the public — and is published in Nature Microbiology (F. Konings et al. Nature Microbiol. https://doi.org/10.1038/s41564-021-00932-w; 2021). It should have come earlier, because its absence has fuelled the practice of naming variants after the places in which they were discovered — such as the ‘Kent variant’, which is otherwise known as B.1.1.7. Under the WHO’s new system, B.1.1.7 is also called Alpha. The B.1.617.2 lineage, first identified in India, is now called Delta. The new system is both a more user-friendly alternative and designed to reduce the geographical stigma and discrimination that can come from associating a virus with a place. It’s also important because, when countries are singled out by news organizations that have millions of readers and viewers, governments can become hesitant. They might delay collecting data on coronavirus strains, or announcing new variants, to avoid what they perceive as negative publicity or the risk of being blamed for creating a variant. The new system does not change the alphanumeric nomenclature systems that researchers use. It also does not prevent the naming of a location where a virus variant has been identified, for example to indicate areas where variants are spreading. What it does do is provide an alternative to names that mean little to people outside research. Coronavirus variants get Greek names — but will scientists use them? At Nature, we will for now be using both the Greek letters and the nomenclature used by researchers, depending on the context, and will continue to avoid labelling variants by their geographical origin. Nature’s news team polled readers on whether they would use the new system. Most of the 1,362 respondents indicated that they would — depending on the context. However, around 15% said they would continue to use geographical descriptors. And more than a week after the WHO’s announcement, some media organizations and prominent people are continuing to identify variants by geographical place names. That needs to end. The letters of the Greek alphabet are well known to international media and policymakers. The WHO system’s authors will be aware that theirs is a temporary solution. The WHO has already used 10 of its 24 letters to describe 6 variants of interest and 4 variants of concern that have been identified since December 2020. This means that a new naming system might need to be found. Developing a naming system that is clear, intelligible and can work across cultures and languages is a complex process — which is one reason it has taken so long for the WHO’s advisers to come up with its present solution. The World Meteorological Organization faces an analogous problem. It has a rotating list of 21 names for storms, such as Dolly and Omar. It also has a reserve list of all 24 Greek letters that it uses when the names in its standard list run out. But in March, it announced that it is retiring the Greek letters from its reserve list and adopting a new system of A–Z names, including Aidan and Zoe. The reason, it says, is that Greek letters can cause confusion when translated into other languages, and that some letters — such as eta and theta — sound alike and might be confused with each other. The WHO’s advisers need to keep working on the next iteration so that it is ready to be deployed when required, and they should consider alphabets from other languages. Their present solution, although not perfect, is a simple, straightforward alternative for variants that are otherwise being named after places. It will reduce the use of geographical origins as the default when referring to variants, and thus avoid an unintended stigma. Nature 594, 149 (2021) doi: https://doi.org/10.1038/d41586-021-01508-8 Jobs from Nature Careers All jobs Postdoctoral Fellow, Statistical Methodologies for Metabolomics Data Analysis The University of British Columbia (UBC) Vancouver, Canada JOB POST Postdoctoral Fellow in River Dynamics The University of British Columbia (UBC) Vancouver, Canada JOB POST PhD Student in Wnt signaling German Cancer Research Center in the Helmholtz Association (DKFZ) Heidelberg, Germany JOB POST Postdoc (all genders), Department Detector Laboratory (DTL) Helmholtz Centre for Heavy Ion Research GmbH (GSI) Darmstadt, Germany JOB POST Download PDF Related Articles SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse Coronavirus variants get Greek names — but will scientists use them? The world needs a single naming system for coronavirus variants This article was downloaded by calibre from https://www.nature.com/articles/d41586- 021-01508-8 | Section menu | Main menu | | Next | Section menu | Main menu | Previous | EDITORIAL 09 June 2021 Google’s AI approach to microchips is welcome — but needs care Artificial intelligence can help the electronics industry to speed up chip design. But the gains must be shared equitably. Download PDF A clean room in a microchip fabrication plant in Singapore.Credit: Lauryn Ishak/Bloomberg/Getty One of the many consequences of the COVID-19 pandemic is a global shortage of the microchips that are essential to electronic devices. The factories that make these chips had to shut down for some of the pandemic, and are struggling to cope with an increase in demand. Some products could be delayed by months. It’s too early to know how the shortage will affect the industry in the long term, but the pandemic has focused attention on some key research questions — including how to make the manufacturing process more resilient to shocks and emergencies. One well-known problem is that microchips are designed in just a handful of companies, including Samsung in South Korea and Intel, NVIDIA and Qualcomm in California. But not all these companies make the chips. Some do; others outsource the work to third parties. And around 80% of the chips are made in Asia (Nature Electron. 4, 317; 2021). The biggest manufacturer is the Taiwan Semiconductor Manufacturing Company (TSMC) in Hsinchu, which is responsible for 28% of global capacity using current fabrication methods. Although this concentration has undoubtedly been of great benefit to the region, it has also contributed to the current restriction of supplies. Signs of change are starting to emerge. China, the United States and some European countries are increasing investments in microchip research and development. Amazon, Google, Microsoft and other big US technology corporations are doing the same, with investments estimated at hundreds of millions of dollars. Spreading capability through more companies — and to more low- and middle-income countries — will help to make the industry more resilient. Time-savers Also of help is a report this week that researchers at Google have managed to greatly reduce the time needed to design microchips (A.

  1045
Recommended publications
  • Honouring the Peasants Day 2 MARCH 2021 2 NATIONAL the GLOBAL NEW LIGHT of MYANMAR
    WEATHER-BASED INSURANCE KEY TO EASING IMPACT OF CLIMATE CHANGE ON FARMERS PAGE-8 (OPINION) Vol. VII, No. 320, 4th Waning of Tabodwe 1382 ME www.gnlm.com.mm Tuesday, 2 March 2021 State Administration Council Chairman Senior General Min Aung Hlaing sends Message of Greetings on Peasants Day Esteemed peasants, Esteemed peasants, Today is a historic day, which honours the peasants all over the country. Peas- The Ministry of Agriculture, Livestock and Irrigation (MOALI) is cooperating ants, I wish you all health and happiness and auspiciousness on this significant with the relevant ministries in distributing advanced technology for the availa- day and also pray for success in your agricultural undertakings. bility of quality strains, water, anti-pest measures, and smooth transport for the Agricultural products not only serve as the backbone of the food industry but agricultural products to reach local and foreign markets in order to produce also as the main source of income for millions of rural people. As agriculture is crops, meat and fish of high quality. shaping the development models of the economy, social affairs and environment, The MOALI is the main body for the development of the agriculture sector, its growth has been realized as the main task of the State. and apart from distributing pedigree strains and technology to enable farmers Peasants are the food-providers and benefactors of the country as their hard to raise or cultivate or produce quality crops and farm animals, it is also helping work helps ensure daily food supplies for the people, generate employment oppor- farmers to apply good agricultural practices (GAP), good animal husbandry tunities and earn foreign exchange income from export.
    [Show full text]
  • Fall 2016 Is Available in the Laboratory of Dr
    RNA Society Newsletter Aug 2016 From the Desk of the President, Sarah Woodson Greetings to all! I always enjoy attending the annual meetings of the RNA Society, but this year’s meeting in Kyoto was a standout in my opinion. This marked the second time that the RNA meeting has been held in Kyoto as a joint meeting with the RNA Society of Japan. (The first time was in 2011). Particular thanks go to the local organizers Mikiko Siomi and Tom Suzuki who took care of many logistical details, and to all of the organizers, Mikiko, Tom, Utz Fischer, Wendy Gilbert, David Lilley and Erik Sontheimer, for putting together a truly exciting and stimulating scientific program. Of course, the real excitement in the annual RNA meetings comes from all of you who give the talks and present the posters. I always enjoy meeting old friends and colleagues, but the many new participants in this year’s meeting particularly encouraged me. (Continued on p2) In this issue : Desk of the President, Sarah Woodson 1 Highlights of RNA 2016 : Kyoto Japan 4 Annual Society Award Winners 4 Jr Scientist activities 9 Mentor Mentee Lunch 10 New initiatives 12 Desk of our CEO, James McSwiggen 15 New Volunteer Opportunities 16 Chair, Meetings Committee, Benoit Chabot 17 Desk of the Membership Chair, Kristian Baker 18 Thank you Volunteers! 20 Meeting Reports: RNA Sponsored Meetings 22 Upcoming Meetings of Interest 27 Employment 31 1 Although the graceful city of Kyoto and its cultural months. First, in May 2016, the RNA journal treasures beckoned from just beyond the convention instituted a uniform price for manuscript publication hall, the meeting itself held more than enough (see p 12) that simplifies the calculation of author excitement to keep ones attention! Both the quality fees and facilitates the use of color figures to and the “polish” of the scientific presentations were convey scientific information.
    [Show full text]
  • Devonian Plant Fossils a Window Into the Past
    EPPC 2018 Sponsors Academic Partners PROGRAM & ABSTRACTS ACKNOWLEDGMENTS Scientific Committee: Zhe-kun Zhou Angelica Feurdean Jenny McElwain, Chair Tao Su Walter Finsinger Fraser Mitchell Lutz Kunzmann Graciela Gil Romera Paddy Orr Lisa Boucher Lyudmila Shumilovskikh Geoffrey Clayton Elizabeth Wheeler Walter Finsinger Matthew Parkes Evelyn Kustatscher Eniko Magyari Colin Kelleher Niall W. Paterson Konstantinos Panagiotopoulos Benjamin Bomfleur Benjamin Dietre Convenors: Matthew Pound Fabienne Marret-Davies Marco Vecoli Ulrich Salzmann Havandanda Ombashi Charles Wellman Wolfram M. Kürschner Jiri Kvacek Reed Wicander Heather Pardoe Ruth Stockey Hartmut Jäger Christopher Cleal Dieter Uhl Ellen Stolle Jiri Kvacek Maria Barbacka José Bienvenido Diez Ferrer Borja Cascales-Miñana Hans Kerp Friðgeir Grímsson José B. Diez Patricia Ryberg Christa-Charlotte Hofmann Xin Wang Dimitrios Velitzelos Reinhard Zetter Charilaos Yiotis Peta Hayes Jean Nicolas Haas Joseph D. White Fraser Mitchell Benjamin Dietre Jennifer C. McElwain Jenny McElwain Marie-José Gaillard Paul Kenrick Furong Li Christine Strullu-Derrien Graphic and Website Design: Ralph Fyfe Chris Berry Peter Lang Irina Delusina Margaret E. Collinson Tiiu Koff Andrew C. Scott Linnean Society Award Selection Panel: Elena Severova Barry Lomax Wuu Kuang Soh Carla J. Harper Phillip Jardine Eamon haughey Michael Krings Daniela Festi Amanda Porter Gar Rothwell Keith Bennett Kamila Kwasniewska Cindy V. Looy William Fletcher Claire M. Belcher Alistair Seddon Conference Organization: Jonathan P. Wilson
    [Show full text]
  • Covid-19: South Africa Pauses Use of Oxford Vaccine After
    NEWS BMJ: first published as 10.1136/bmj.n372 on 8 February 2021. Downloaded from The BMJ Cite this as: BMJ 2021;372:n372 Covid-19: South Africa pauses use of Oxford vaccine after study casts http://dx.doi.org/10.1136/bmj.n372 doubt on efficacy against variant Published: 08 February 2021 Elisabeth Mahase Rollout of the Oxford-AstraZeneca covid-19 vaccine is going to be hard to estimate. Without seeing results in South Africa has been paused after a study in 2000 in detail it isn’t possible to be sure how firm these healthy and young volunteers reported that it did not conclusions are. protect against mild and moderate disease caused by “However, if the press reports are correct it does seem the new variant (501Y.V2) that emerged there. of concern that protection against disease was not The study, which has not been published and was shown. The findings of the Novavax vaccine trial of seen by the Financial Times,1 looked at the efficacy 60% efficacy in the prevention of disease of any of the vaccine against the 501Y.V2 variant—which severity in HIV negative volunteers in South Africa accounts for around 90% of cases in South Africa—in might also suggest that vaccines will need to be HIV negative people. While reports suggested that updated in line with emerging mutations of the the vaccine was ineffective at preventing mild to virus.” moderate disease in that population, no data have 1 Mancini DP, Kuchler H, Pilling D, Cookson C, Cotterill J. Oxford/AstraZeneca been made available to the public.
    [Show full text]
  • COVID-19 Vaccination in Patients with Liver Disease
    COVID-19 Vaccination in Patients with Liver Disease Moderated By: Kyong-Mi Chang, MD, FAASLD & Gregory A. Poland, MD © 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG Webinar Moderator Kyong-Mi Chang, MD, FAASLD • Professor of Medicine (GI) – University of Pennsylvania Perelman School of Medicine • Associate Chief of Staff and Associate Dean for Research at the affiliated Corporal Michael J. Crescenz VA Medical Center in Philadelphia © 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG 2 Webinar Moderator Gregory A. Poland, MD • Mary Lowell Leary Professor of Medicine at the Mayo Clinic in Rochester, Minnesota • Director of the Mayo Clinic's Vaccine Research Group © 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG 3 Webinar Agenda Talks Speakers Webinar and Presenter Introductions Dr. Chang & Poland "Safety and efficacy of conventional vaccination in patients with liver Dr. Hugo Rosen disease” “Safety of vaccines with adenoviral vectors in liver disease patients” Prof. Eleanor Barnes “Safety of RNA vaccines in liver disease patients” - Moderna Dr. Drew Weissman “Safety of RNA vaccines in liver disease patients” - Pfizer Dr. Onyema Ogbuagu Panel Discussion / Q&A All © 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG 4 Webinar Q&A • Submit your questions anytime during the webinar in the Q&A box at the top or bottom of your screen. • Questions will be answered at the end of the presentations. © 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG 5 Webinar Presenter Hugo R. Rosen, MD, FAASLD • Professor and Chair, Department of Medicine • Kenneth T.
    [Show full text]
  • Novavax Covid Vaccine Protects People Against
    University of Witwatersrand in Johannesburg. The 501Y.V2 lineage spread so rapidly that it caused nearly all of the COVID-19 cases that the trial recorded. In the group of people who received two vaccine doses, 15 developed COVID-19, compared with 29 of the participants who received a placebo injection. This equates to an efficacy of 49.4%. The study enrolled 240 people who are HIV-positive, and when Madhi’s team excluded this group from the analysis, the vaccine was 60% effective. Madhi says that he’d expected the vaccine to perform much worse against 501Y.V2 than against other variants. That’s because emerg- ing data had shown that the variant was imper- vious to many of the potent ‘neutralizing’, or virus-blocking, antibodies generated by people who had received other vaccines or had recovered from infection. “A vaccine efficacy of 60% is something which I certainly didn’t dream of when I started to see all of the other PA IMAGES/ALAMY PA data that was coming out.” Novavax’s protein-based vaccine relies on tried-and-tested technology. The South African trial was not large enough to determine whether the vaccine is better at preventing severe cases of COVID-19 than it is at preventing milder infections. But evidence NOVAVAX COVID VACCINE that other COVID-19 vaccines work in this way suggests that the Novavax jab will do, too, says PROTECTS PEOPLE Madhi. “I believe this vaccine will impact on hospitalization and severe disease, probably AGAINST VARIANTS north of 60%.” Trial data also suggested that people who But the experimental shot saw a worrying drop in had previously been infected with the original lineage were not protected against re- infection efficacy against a lineage detected in South Africa.
    [Show full text]
  • What If We Could Make RNA Accessible to Everyone?
    What if we could make RNA accessible to everyone? Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 1 Disclaimer Caution Regarding Forward Looking Statements Certain statements included in this Investor Presentation (“Presentation”) that are not historical facts are forward-looking statements for purposes of US law. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “pipeline”, “predict,” “project,” “forecast,” “potential,” “seem,” “seek,” “strategy,” “future,” “outlook,” “opportunity,” “should,” “would,” “will be,” “will continue,” “will likely result” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding operating results, product field tests, clinical trials, future liquidity, the proposed transaction between Environmental Impact Acquisition Corporation ("ENVI") and GreenLight, including statements as to the expected timing, funding, completion and effects of the Proposed Business Combination or other steps or transactions associated with it and financial estimates, forecasts, and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of the respective management of GreenLight and Environmental Impact Acquisition Corporation ("ENVI") and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
    [Show full text]
  • The Pandemic Pipeline Companies Are Doing Their Best to Accelerate Experimental Drugs and Vaccines for COVID-19 Through the Pipeline
    news feature Credit: Plrang GFX / Alamy Stock Photo The pandemic pipeline Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics. John Hodgson his week, Moderna Therapeutics’ of the mRNA vaccine could reach clinics as Approved small molecules are already in use modified mRNA vaccine for COVID- early as 2021. This will be too late for the off label as adjunct therapies for critically ill T19 began phase 1 clinical testing. current pandemic. And given that no mRNA patients (like Fujifilm Toyama Chemical’s From the first description of the novel vaccine has ever been approved, mRNA- favipiravir), with several other experimental coronavirus (SARS-CoV-2) genome on 10 1273 faces numerous challenges in clinical drugs (like Gilead’s remesdivir) under January, it took the company just 42 days development and manufacture before it has investigation. Repurposed monoclonal to produce the first batches of its vaccine the possibility of being made available for antibodies (mAbs) developed against (mRNA-1273), which encodes a prefusion- global immunization. previous coronaviruses, such as severe stabilized form of the SARS-CoV-2 spike (S) In the meantime, a host of other acute respiratory syndrome (SARS) virus protein. If it can successfully negotiate safety therapeutic modalities are being accelerated and Middle Eastern respiratory syndrome and efficacy testing on a larger scale, batches through discovery and development. (MERS) virus, promise passive immunity NATURE BIOTECHNOLOGY | VOL 38 | MAY 2020 | 523–532 | www.nature.com/naturebiotechnology 523 news feature College in London, agrees.
    [Show full text]
  • 2014 HRP Annual Report
    National Aeronautics and Space Administration HUMAN RESEARCH PROGRAM 2014 Fiscal Year Annual Report New Ideas. Meaningful Research. Promising Results. MESSAGE FROM THE PROGRAM MANAGER The Human Research Program (HRP) continues to make excellent progress toward under- standing and mitigating the health and performance risks that challenge NASA’s ability to fly exploration missions beyond low Earth orbit. Our access to space this year was unprecedented; our access to medical data improved substantially; our cooperation with international partners expanded; and, for the first time, NASA engineers asked for our requirements before beginning to design a new space vehicle. By any measure, FY2014 was a banner year with numerous accomplishments, and I am honored to share some of our significant highlights. The life extension of the International Space Station formance (BHP) Element risk reduction goals, which (ISS) to 2024 announced earlier this year was in part are among the most participant-intensive in our PRR. due to the HRP Path to Risk Reduction (PRR). The PRR clearly demonstrated our planned flight research The ISS-commissioned Multilateral Human Re- could not be completed with the number of crew search Panel for Exploration (MHRPE), led by our slated to fly before its previous decommission date of own Dr. John Charles, had a successful year devel- 2020. While this eased our concerns, there are still oping the hardware, data, and subject sharing plans likely too few flight subjects to answer all key re- to facilitate the first one-year ISS mission. A group search questions. To address this limitation, we began of multinational experiments were selected for this working closely with the Human pilot mission—launching in early System Risk Board to ensure the 2015—which will refine our un- likelihood and consequences of derstanding of extended mission each of the risks in our PRR were durations on crew health and accurately assessed.
    [Show full text]
  • Shabir a Madhi Professor Shabir Madhi Date of Birth: 28 November 1966 Nationality: South African
    CURRICULUM VITAE : Shabir A Madhi Professor Shabir Madhi Date of Birth: 28 November 1966 Nationality: South African 1. Most Recent Current and Past Work Positions: i). Executive Director: National Institute for Communicable Diseases, National Health Laboratory Service. (2011-Current) ii). Professor of Vaccinology; School of Pathology; Univ. of Witwatersrand (2008-current) iii). Chair: Department of Science and Technology/ National Research Foundation – Vaccine Preventable Diseases. (2008 -current) iv). Co-director: University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit. (2007 -2013) v). Director: University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit. (2007 -2013) vi). Honorary Consultant: Department of Paediatrics. (1997 -2005) 2. PROFESSIONAL QUALIFICATIONS 1990: Bachelor of Medicine and Bachelor of Surgery (MBBCh); University of the Witwatersrand, Johannesburg 1996: Fellow College of Paediatrics (FCPaeds (SA); College of Medicine of South Africa 1998: Masters in Medicine (MMed Paediatrics); University of the Witwatersrand, Johannesburg 2001-2010: Sub-speciality registration - Critical Care Paediatrics. Health Professional Council of South Africa 2003: PhD (Health Sciences); University of the Witwatersrand, Johannesburg. 2010: Sub-speciality registration – Infectious Diseases. Health Professional Council of South Africa 3. MEMBERSHIP OF PROFESSIONAL BODIES/ASSOCIATIONS i). Member: South African Medical Association (1996-) ii). Fellow: College of South Africa (1997-) iii). Member: South African Paediatric Association (1997-) iv). Member: Critical Care Society of South Africa. (2002-2009) v). Member: Federation of Infectious Diseases Society of South Africa. (2002-) vi). Member: European Society of Paediatric Infectious Diseases (2003-) vii). Deputy-president: Southern African Society of Infectious Diseases (2008-2013) viii). Board member : International Scientific Committee – World Society of Paediatric Infectious Diseases (2008-2013) ix).
    [Show full text]
  • Want to Know More About Mrna Before Your COVID Jab?
    Want to Know More About mRNA Before Your COVID Jab? — A primer on the history, scope, and safety of mRNA vaccines and therapeutics by Kristina Fiore, Director of Enterprise & Investigative Reporting, MedPage Today December 3, 2020 Clinicians will start rolling up their sleeves in just a few weeks to get their first doses of COVID-19 vaccines, both of which use mRNA technology to induce an immune response. For those who want more information on the history and science of mRNA vaccines and therapeutics before getting their jab, here's a primer. How It Works Biologically, messenger RNA is transcribed from DNA and travels into a cell's cytoplasm where it's translated by ribosomes into proteins. For the Pfizer/BioNTech and Moderna vaccines, the synthesized mRNA is cloaked in a lipid nanoparticle in order to evade the immune system when it's injected. Once it's inside a cell, the ribosomes will get to work pumping out the spike protein of SARS-CoV-2. The immune system then mounts a response to that protein, conferring immunity to the virus without ever having been infected by it. Essentially, instead of pharma producing the proteins via an expensive and difficult process, mRNA enlists the body to do the work. The capability to produce mRNA so rapidly is one reason these vaccines are out front in the global race for a COVID-19 vaccine. Never Been Done Before? That's not completely true. While an mRNA vaccine has never been on the market anywhere in the world, mRNA vaccines have been tested in humans before, for at least four infectious diseases: rabies, influenza, cytomegalovirus, and Zika.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 7 Giugno 2021
    Coronavirus: quello che c’è da sapere – 7 giugno 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Qual è l’origine del virus? .........................................................................4 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................46 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]